Skip to main content
Novartis Home
language-selector-globe Global | en
Choose Location
  • International
  • Americas
  • Asia Pacific
  • Europe
  • Middle East & Africa
Global | en
Sandoz | en
Novartis Foundation | en
Argentina | es
Brazil | pt
Canada | en
Canada | fr
Central America | es
Colombia | es
Mexico | es
United States | en
Venezuela | es
Australia | en
Bangladesh | en
Hong Kong S.A.R. | zh
India | en
Indonesia | en
Japan | ja
Korea | ko
Mainland China | zh
Malaysia | en
Pakistan | en
Philippines | en
Singapore | en
Taiwan | zh
Thailand | th
Austria | de
Belgium | fr
Belgium | nl
Bulgaria | bg
Czech Republic | cs
Czech Republic | en
Denmark | da
Estonia | et
Finland | fi
France | fr
Germany | de
Greece | el
Hungary | hu
Ireland | en
Italy | it
Latvia | lv
Lithuania | lt
Netherlands | nl
Norway | no
Poland | pl
Portugal | pt
Romania | ro
Russia | ru
Serbia | sr
Slovakia | sk
Spain | es
Sweden | sv
Switzerland | de
Switzerland | fr
United Kingdom | en
Egypt | en
Israel | he
Saudi Arabia | ar
South Africa | en
Turkey | tr
language-selector-globe Global
Choose Location
International Americas Asia Pacific Europe Middle East & Africa
Argentina | es
Australia | en
Austria | de
Bangladesh | en
Belgium | fr
Belgium | nl
Brazil | pt
Bulgaria | bg
Canada | en
Canada | fr
Central America | es
Colombia | es
Czech Republic | cs
Czech Republic | en
Denmark | da
Egypt | en
Estonia | et
Finland | fi
France | fr
Germany | de
Greece | el
Hong Kong S.A.R. | zh
Hungary | hu
India | en
Indonesia | en
Ireland | en
Israel | he
Italy | it
Japan | ja
Korea | ko
Latvia | lv
Lithuania | lt
Mainland China | zh
Malaysia | en
Mexico | es
Netherlands | nl
Norway | no
Global | en
Sandoz | en
Novartis Foundation | en
Pakistan | en
Philippines | en
Poland | pl
Portugal | pt
Romania | ro
Russia | ru
Saudi Arabia | ar
Serbia | sr
Singapore | en
Slovakia | sk
South Africa | en
Spain | es
Sweden | sv
Switzerland | de
Switzerland | fr
Taiwan | zh
Thailand | th
Turkey | tr
United Kingdom | en
United States | en
Venezuela | es
    • About 
      • Board of Directors 
        • Joerg Reinhardt 
        • Simon Moroney 
        • Nancy C. Andrews 
        • Ton Buechner 
        • Patrice Bula 
        • Elizabeth (Liz) Doherty 
        • Ana de Pro Gonzalo 
        • Bridgette Heller 
        • Daniel Hochstrasser 
        • Frans van Houten 
        • Charles L. Sawyers 
        • William T. Winters 
        • John D. Young 
        • Charlotte Pamer-Wieser 
      • Executive Committee 
        • Vasant (Vas) Narasimhan 
        • Shreeram Aradhye 
        • Victor Bulto 
        • Aharon (Ronny) Gal 
        • Karen L. Hale 
        • Harry Kirsch 
        • Rob Kowalski 
        • Steffen Lang 
        • Fiona Marshall 
        • Klaus Moosmayer 
        • Lutz Hegemann 
        • Mukul Mehta 
        • Kees Roks 
        • Richard Saynor 
        • Michelle Weese 
      • Strategy 
        • People and Culture 
        • Data and Digital 
      • Products 
      • Innovative Medicines 
      • Therapeutic areas 
        • Hematology 
        • Neuroscience 
        • Solid tumors 
      • Sandoz 
      • Diversity, Equity & Inclusion 
        • Equity 
        • Diversity, Equity & Inclusion Governance and Community 
        • Inclusivity 
        • Parental Leave 
        • Society 
      • Manufacturing 
      • Quality 
        • Audit program 
        • Novartis Quality Management System (QMS) 
        • Product and patient safety training 
        • Regulatory inspections 
        • Product recalls 
        • Third-party suppliers 
      • Awards and Recognition 
      Male scientist in lab

      About

      Learn about how Novartis is organized and our strategy, vision and mission. Meet our people and read about our commitments to diversity, equity and inclusion. Explore our history which goes back more than 250 years.

    • Patients and Caregivers 
      • Novartis Commitment to Patients and Caregivers 
      • Diseases 
      • Patient Organization Funding 
      • Stories: Patients Perspectives 
      Couple holding hands

      Patients and Caregivers

      Information for patients and their caregivers including clinical trial recruiting, managed access programs, funding opportunities for patient organizations and side effects reporting.

    • Healthcare Professionals 
      • Medical Congresses and Events 
        • Abstract summaries for EULAR 
        • Abstract summaries for ACR 
        • ASCO Annual Meeting 
      • Products 
      • Novartis Pipeline 
      • Managed Access Programs 
        • Novartis Gene Therapies Managed Access Program 
      • Novartis External Funding 
      • Healthcare Professional Resources by Country 
      • Investigator-Initiated Trials / Studies 
      • Transparency and Disclosure 
      • Novartis Medical Information 
        • Submit medical enquiry 
      Doctor

      Healthcare Professionals

      Resources for physicians and other healthcare professionals including clinical trial recruiting, grant funding, congresses and country-level information.

    • Research & Development 
      • Novartis Institutes for BioMedical Research 
        • Collaborations 
        • NIBR Global Scholars Program 
      • Technology Platforms 
      • Research Disease Areas 
        • Cardiovascular and metabolic disease research at Novartis 
        • DAx: exploratory disease research at Novartis 
        • Global Health disease area research at Novartis 
        • Immunology disease research at Novartis 
        • Neuroscience research at Novartis 
        • Oncology research at Novartis 
        • Ophthalmology research at Novartis 
      • Novartis Pipeline 
      • Translational Medicine 
      • Research Collaborations 
      • Open Source Science 
      • Stories from our Labs 
      Scientists conducting innovative research experiments

      Research & Development

      Discover how Novartis turns breakthrough science into transformative, high-value treatments.
       

    • ESG 
      • Access 
        • Creating sustainable business models 
        • Value-Based Pricing 
        • Sub-Saharan Africa 
        • Donations 
        • Novartis Access Principles 
        • Novartis Oncology Access 
        • Patents and Licensing 
      • Ethics, Risk and Compliance 
        • Ethical Behavior 
        • Compliance 
        • Human Rights 
        • Learning and Engagement 
        • Risk management 
      • Environmental Sustainability 
        • Climate 
        • Waste 
        • Water 
      • Global Health 
        • Anti-Microbial Resistance (AMR) 
        • Avoidable Blindness 
        • Chagas Disease 
        • Leprosy 
        • Malaria 
        • Sickle Cell Disease (SCD) 
        • Novartis Foundation 
      • Diversity, Equity & Inclusion 
      • Reporting 
        • ESG Rating Performance 
        • Codes, Policies and Guidelines 
        • Materiality Assessment 
        • Transparency and Disclosure 
        • Targets 
        • Positions 
      • ESG Index 
      Young patients waiting outside an hospital in Rwanda

      Environmental, Social and Governance

      Learn about our commitments to making a positive impact on the world by providing access to innovative medicines, protecting the environment, and upholding high ethical standards. Explore the Novartis in Society Integrated Report.

    • Investors 
      • Event Calendar 
      • Financial Data 
        • Novartis Annual Results 
        • Novartis Quarterly Results 
        • Novartis SEC Filings 
        • Product Sales 
        • Fixed-Income Securities 
        • Expected Currency Impact 
      • Share Data & Analysis 
        • Share Monitor 
        • Dividend Information 
        • Share Ownership 
        • Share Overview 
        • Return On Investment Calculator 
      • Shareholder Information 
        • General Meetings 
        • American Depository Receipts (ADR) 
        • Share Buy-Back 
        • Frequently Asked Questions 
      • Company Overview 
        • Corporate Governance 
      • Novartis Annual Reporting Suite 
        • Reporting Archive 
        • Publications Order Form 
      • ESG 
      Hands marking a test tube

      Investors

      Updates and resources for investors including financial information, disclosures, events, share price, ESG and reporting.

    • News 
      • News Archive  
      • Media Library  
      • Stories 
      • Subscribe 
      People at the table with screens

      News

      Information for journalists including media releases, statements, stories, multimedia resources and more.

    • Careers 
      • Career Search 
      • Benefits & Rewards 
      • Career Programs 
        • Community Exploration & Learning Lab (CELL) 
        • Postdoc Program 
      • Early Careers 
        • Careers in Data, Digital & Information Technology (IT) 
        • Careers in Technical Operations 
        • Students 
        • Graduates 
        • US NIBR Internship Programs 
      • Personal Growth 
      • Wellbeing 
      Close-up portrait of a scientist in Cambridge, USA

      Careers

      Novartis is hiring! Find open positions, learn more about our strategy and culture, and apply today.

    • Clinical Trials 
      doctor taking the blood pressure of her patient

      Clinical Trials

      Find recruiting clinical trials and learn more about how to participate or work with Novartis on clinical studies. Read about our clinical trials transparency initiatives.

    • Partnering 
      Business people working in a dark room

      Partnering

      Learn about our approach to partnering which combines capabilities, collaboration and culture.

    • Supplier Portal 
      Group of business people in a meeting area

      Supplier Portal

      Practical information and resources for suppliers around the world.

    • Report side effects 
      Our Mission

      Report side effects

      Let us know about any unwanted medical occurrences.

    • Contacts 
      Office Cubicle

      Contacts

      Get in touch.

    Scientist working in a lab

    Home

    Welcome to Novartis where we are reimagining medicine to improve and extend people’s lives.

Placeholder Image

Ad Hoc

Tags Archive Navigation
  • All
  • Careers
  • Featured News
  • In the News
  • Media Releases
  • Story
icon
  • Media Release
    Sep 05, 2023
    Sandoz veröffentlicht Nachtrag zum Kotierungsprospekt, einschliesslich Finanzabschluss von Sandoz für das 1. Halbjahr 2023
  • Media Release
    Sep 05, 2023
    Sandoz publie un supplément au prospectus de cotation comprenant les états financiers de Sandoz au premier semestre 2023
  • Media Release
    Sep 05, 2023
    Sandoz publishes supplement to Listing Prospectus including Sandoz H1 2023 financial statements
  • Media Release
    Aug 18, 2023
    Novartis publie l’invitation à l’AGE et la brochure d’information aux actionnaires. Sandoz publie le prospectus de cotation avant le vote sur la proposition de scission
  • Media Release
    Aug 18, 2023
    Novartis issues EGM Invitation and Shareholder Information Brochure. Sandoz publishes Listing Prospectus ahead of proposed Spin-off vote
  • Media Release
    Aug 18, 2023
    Novartis publiziert Einladung und Aktionärsbroschüre zur ausserordentlichen Generalversammlung. Sandoz veröffentlicht den Kotierungsprospekt im Vorfeld der Abstimmung zum vorgeschlagenen Spin-off
  • Media Release
    Aug 09, 2023
    Novartis remibrutinib Phase III trials met their primary endpoints and showed rapid symptom control in chronic spontaneous urticaria
  • Media Release
    Jul 18, 2023
    Novartis erzielt kräftige Umsatz- und Margensteigerungen und erhöht die Prognose. Aktienrückkaufprogramm von USD 15 Milliarden angekündigt; der Verwaltungsrat unterstützt den Spin-off von Sandoz¹˒²
  • Media Release
    Jul 18, 2023
    Novartis réalise une forte croissance de son chiffre d’affaires et de sa marge, relève ses prévisions et annonce un rachat d’actions d’USD 15 milliards¹; le Conseil d’administration approuve le spin-off de Sandoz²
  • Media Release
    Jul 18, 2023
    Novartis delivers strong sales growth, robust margin expansion and raises guidance. Announces USD 15 billion share buyback and Board endorses Sandoz spin-off¹˒²
  • Media Release
    Jul 07, 2023
    Novartis will appeal to U.S. Court of Appeals to uphold validity of Entresto® combination patent; maintains 2023 guidance and mid-term outlook
  • Media Release
    Jun 12, 2023
    Novartis bolsters innovative medicines strategy and renal pipeline with agreement to acquire Chinook Therapeutics for USD 3.2bn upfront (USD 40 / share)

Pagination

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • …
  • 15
  • › Next page

Novartis

Navigate Novartis
  • Patients and Caregivers
  • Healthcare Professionals
  • Researchers
  • Job Seekers
  • Journalists
  • Investors
  • Partners
  • Suppliers
Topics
  • Clinical Trials
  • ESG
  • SpeakUp
Explore
  • Novartis Pipeline
  • Products
  • Therapeutic areas
  • Diseases
  • Stories
  • Locations
Novartis companies
  • Sandoz
  • Advanced Accelerator Applications
  • Chinook Therapeutics
  • Gyroscope Therapeutics
Footer Bottom
© 2023 Novartis AG
  • Terms of Use
  • Privacy
  • Contacts
  • Cookie Settings
  • Site Map
  • Web Accessibility
  • Open Source
Novartis Site Directory
This site is intended for a global audience